Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer

A. Johnston-Early, M. H. Cohen, B. E. Fossieck, S. Harwood, D. C. Ihde, P. A. Bunn, M. J. Matthews, J. D. Minna, R. Makuch

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The prognotic importance of pretreatment delayed hypersensitivity skin test reactivity was determined in 154 newly diagnosed, carefully staged and aggressively treated small cell lung cancer patients. One hundred twenty-one patients were reactive to at least 1 of 5 skin test antigens and 33 were anergic. Skin test reactive patients survived significantly longer than anergic patients. This result was expected since there was a significant trend for reactive patients to have good performance status (P = 0.005) and low tumor burden (P= 0.005) compared to anergic patients. The principal finding of this study was that skin test reactivity was of prognostic utility primarily in otherwise good prognosis patients, i.e., individuals with good performance status and low tumor burden. In this group anergy was associated with significantly shortened survival (P = 0.025). In poor prognosis (poor performance status and high tumor burden) or intermediate prognosis (either poor performance status or high tumor burden) patients skin test reactivity or anergy had no significant influence on survival.

Original languageEnglish (US)
Pages (from-to)1395-1140
Number of pages256
JournalCancer
Volume52
Issue number8
StatePublished - 1983

Fingerprint

Small Cell Lung Carcinoma
Delayed Hypersensitivity
Skin Tests
Skin
Tumor Burden
Survival
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnston-Early, A., Cohen, M. H., Fossieck, B. E., Harwood, S., Ihde, D. C., Bunn, P. A., ... Makuch, R. (1983). Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer, 52(8), 1395-1140.

Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. / Johnston-Early, A.; Cohen, M. H.; Fossieck, B. E.; Harwood, S.; Ihde, D. C.; Bunn, P. A.; Matthews, M. J.; Minna, J. D.; Makuch, R.

In: Cancer, Vol. 52, No. 8, 1983, p. 1395-1140.

Research output: Contribution to journalArticle

Johnston-Early, A, Cohen, MH, Fossieck, BE, Harwood, S, Ihde, DC, Bunn, PA, Matthews, MJ, Minna, JD & Makuch, R 1983, 'Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer', Cancer, vol. 52, no. 8, pp. 1395-1140.
Johnston-Early A, Cohen MH, Fossieck BE, Harwood S, Ihde DC, Bunn PA et al. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer. 1983;52(8):1395-1140.
Johnston-Early, A. ; Cohen, M. H. ; Fossieck, B. E. ; Harwood, S. ; Ihde, D. C. ; Bunn, P. A. ; Matthews, M. J. ; Minna, J. D. ; Makuch, R. / Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. In: Cancer. 1983 ; Vol. 52, No. 8. pp. 1395-1140.
@article{b4a5d0365b4443b39f2626c95f85b739,
title = "Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer",
abstract = "The prognotic importance of pretreatment delayed hypersensitivity skin test reactivity was determined in 154 newly diagnosed, carefully staged and aggressively treated small cell lung cancer patients. One hundred twenty-one patients were reactive to at least 1 of 5 skin test antigens and 33 were anergic. Skin test reactive patients survived significantly longer than anergic patients. This result was expected since there was a significant trend for reactive patients to have good performance status (P = 0.005) and low tumor burden (P= 0.005) compared to anergic patients. The principal finding of this study was that skin test reactivity was of prognostic utility primarily in otherwise good prognosis patients, i.e., individuals with good performance status and low tumor burden. In this group anergy was associated with significantly shortened survival (P = 0.025). In poor prognosis (poor performance status and high tumor burden) or intermediate prognosis (either poor performance status or high tumor burden) patients skin test reactivity or anergy had no significant influence on survival.",
author = "A. Johnston-Early and Cohen, {M. H.} and Fossieck, {B. E.} and S. Harwood and Ihde, {D. C.} and Bunn, {P. A.} and Matthews, {M. J.} and Minna, {J. D.} and R. Makuch",
year = "1983",
language = "English (US)",
volume = "52",
pages = "1395--1140",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer

AU - Johnston-Early, A.

AU - Cohen, M. H.

AU - Fossieck, B. E.

AU - Harwood, S.

AU - Ihde, D. C.

AU - Bunn, P. A.

AU - Matthews, M. J.

AU - Minna, J. D.

AU - Makuch, R.

PY - 1983

Y1 - 1983

N2 - The prognotic importance of pretreatment delayed hypersensitivity skin test reactivity was determined in 154 newly diagnosed, carefully staged and aggressively treated small cell lung cancer patients. One hundred twenty-one patients were reactive to at least 1 of 5 skin test antigens and 33 were anergic. Skin test reactive patients survived significantly longer than anergic patients. This result was expected since there was a significant trend for reactive patients to have good performance status (P = 0.005) and low tumor burden (P= 0.005) compared to anergic patients. The principal finding of this study was that skin test reactivity was of prognostic utility primarily in otherwise good prognosis patients, i.e., individuals with good performance status and low tumor burden. In this group anergy was associated with significantly shortened survival (P = 0.025). In poor prognosis (poor performance status and high tumor burden) or intermediate prognosis (either poor performance status or high tumor burden) patients skin test reactivity or anergy had no significant influence on survival.

AB - The prognotic importance of pretreatment delayed hypersensitivity skin test reactivity was determined in 154 newly diagnosed, carefully staged and aggressively treated small cell lung cancer patients. One hundred twenty-one patients were reactive to at least 1 of 5 skin test antigens and 33 were anergic. Skin test reactive patients survived significantly longer than anergic patients. This result was expected since there was a significant trend for reactive patients to have good performance status (P = 0.005) and low tumor burden (P= 0.005) compared to anergic patients. The principal finding of this study was that skin test reactivity was of prognostic utility primarily in otherwise good prognosis patients, i.e., individuals with good performance status and low tumor burden. In this group anergy was associated with significantly shortened survival (P = 0.025). In poor prognosis (poor performance status and high tumor burden) or intermediate prognosis (either poor performance status or high tumor burden) patients skin test reactivity or anergy had no significant influence on survival.

UR - http://www.scopus.com/inward/record.url?scp=0020557731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020557731&partnerID=8YFLogxK

M3 - Article

C2 - 6311393

AN - SCOPUS:0020557731

VL - 52

SP - 1395

EP - 1140

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -